1461 citations
,
March 2004 in “Annals of oncology” This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.
522 citations
,
January 2001 in “Cancer investigation” This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.
388 citations
,
September 2000 in “Cancer” This study observed that the toxicity of Doxil in metastatic breast carcinoma patients is both dose and schedule dependent, with clear correlations to pharmacokinetic parameters.
108 citations
,
December 2003 in “Clinical breast cancer” The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.
This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.